Nasal Carriage of Staphylococcus aureus does not affect the Clinical Response to Immunotherapy in Allergic Rhinitis Patients | ||||
| Egyptian Journal of Medical Microbiology | ||||
| Volume 27, Issue 4, October 2018, Page 1-6 PDF (297.74 K) | ||||
| Document Type: New and original researches in the field of Microbiology. | ||||
| DOI: 10.21608/ejmm.2018.285604 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Sahar Zakaria Elazab 
| ||||
| Department of Medical Microbiology and Immunology, Faculty of Medicine, Suez Canal University, Egypt. | ||||
| Abstract | ||||
| Background: Nasal carriage of Staphylococcus aureus (NCSA) is frequent in patients with allergic rhinitis (AR). Allergen immunotherapy is safe and effective in the treatment of AR. Objective: The present work aims to assess the effect of NCSA on the clinical response to immunotherapy (IT) in AR patients. Methodology: Assessment of symptom severity was done by visual analogue scale in 25 NCSA-positive and 25 NCSA-negative AR patients. Patients were treated by cluster IT for 8 weeks after which symptom severity was reassessed. Results: Before IT, NCSA-positive patients showed significant increase in rhinorrhea, sneezing, and nasal blockage than NCSA-negative patients. No significant difference was observed in non-nasal symptoms or total symptom severity scores. After IT, there was no difference in the severity of nasal and non-nasal symptoms between the two groups. Clinical improvement was more noticeable in NCSA-positive than NCSA-negative patients; however, the difference is non-significant. Conclusion: NCSA does not affect the clinical response to immunotherapy in AR patients. | ||||
| Keywords | ||||
| Staphylococcus aureus; nasal carriage; allergic rhinitis; immunotherapy | ||||
|
Statistics Article View: 37 PDF Download: 27 |
||||
